Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus

Modern Pathology

Volumn 12, Issue 3, 1999, Pages 239-250

  Soslow, Robert A ^a   Remotti, Helen ^a   Baergen, Rebecca N ^a   Altorki, Nasser K ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Barrett's esophagus; Cell cycle; Esophageal adenocarcinoma

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; RETINOBLASTOMA PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MALE; PATHOGENESIS; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; AGED; APOPTOSIS; BARRETT ESOPHAGUS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL CYCLE; CELL DIVISION; CYCLIN D1; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PARIETAL CELLS, GASTRIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN;

EID: 0032971532     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-6.
2. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
3. Ishida M, Gomyo Y, Tatebe S, Ohfuji S, Ito H. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling. Virchows Arch 1996;428:229-35.
4. Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
5. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
6. Oltvai ZN, Milliman CL, Korsmeyer SJ. bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19.
7. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
8. Goldblum JR, Rice TW. bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence. Mod Pathol 1995;8:866-9.
9. 1 to S-phase transition. Annu Rev Cell Biol 1992;8:529-61.
10. Boynton RF, Huang Y, Blount PL, Reid BJ, Raskind WH, Haggitt RC, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancer. Cancer Res 1991;51:5766-9.
11. Gaffey MJ, Iezzoni JC, Meredith SC, Boyd JC, Stoler MH, Weiss LM, et al. Cyclin D1 (PRAD1, CCND1) and glutathione-s-transferase π gene expression in head and neck squamous cell carcinoma. Hum Pathol 1995;26:1221-6.
12. Arber N, Lightdale C, Rotterdam H, Han KH, Sgambato A, Yap E, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996;5:457-9.
13. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
14. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994;35:764-8.
15. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993;105:1637-42.
16. Hamelin R, Flejou J-F, Muzeau F, Potet F, Laurent-Puig P, Fekete F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
17. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991;51: 5482-6.
18. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus: correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11.
19. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histologic progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
20. Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology. Series 3, Fasc. 18. Washington, DC: Armed Forces Institute of Pathology; 1995. p. 99-139.
21. Peiro G, Lerma E, Climent MA, Segui MA, Alonso MC, Prat J. Prognostic value of S-phase fraction in lymph-node-negative breast cancer by image and flow cytometric analysis. Mod Pathol 1997;10:216-22.
22. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
23. Hilsenbeck S, Allred D. Improved methods of estimating mitotic activity in solid tumors. Hum Pathol 1992;23:610-2.
24. van Diest P, Baak J, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH, et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992;23:603-7.
25. Remmele W, Schicketanz K-H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862-6.
26. Makkink-Nombrado SV, Baak JP, Schuurmans L, Theeuwes JW, van der Aa T. Quantitative immunohistochemistry using the CAS 200/486 image analysis system in invasive breast carcinoma: a reproducibility study. Anal Cell Pathol 1995;8: 227-45.
27. Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, et al. Apoptosis is inhibited early in the dysplasiacarcinoma sequence of Barrett esophagus. Arch Surg 1997; 132:728-33.
28. Lauwers GY, Kandemir O, Kubilis PS, Scott GV. Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation. Mod Pathol 1997;10:1201-8.
29. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
30. Koshida Y, Saegusa M, Okayasu I. Apoptosis, cell proliferation and expression of bcl-2 and bax in gastric carcinomas: immunohistochemical and clinicopathologic study. Br J Cancer 1997;75:367-73.
31. Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, et al. Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996;149:1449-57.
32. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
33. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
34. Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A 1992;89:3385-8.
35. Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, et al. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 1992;52:3231-3.
36. Lu S-H, Hsieh L-L, Luo F-C, Weinstein IB. Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer 1988;42:502-5.
37. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RS. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22.
38. Soslow RA, Ying L, Altorki NK. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma. J Thorac Cardiovasc Surg 1997;114: 838-43.